Fareeha Siddiqui MD in San Diego, California

Additional Medical Specialties Include:
MEDICAL ONCOLOGY

Medical School: Sorry, her university is not listed
Graduation Year: 1998
The Primary Medical Specialty for Fareeha Siddiqui MD is listed as: Hematology/oncology
Credentials: MD
Additional Credentials:
Approximate Years of Experience: 26
PAC (PECOS ID)#: 5890793368
NPI #: 1104848720
NPI Created On: 07/24/2006
NPI Last Updated Listed as: 05/27/2021
Primary Taxonomy Code: 207RX0202X
License Number:
A108879
Listed Gender: Female

Forms of insurance accepted by include, but are not limited to:

• Humana
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English, Spanish.

Services and Procedures include:

1. Insertion of needle into vein for collection of blood sample
2. Complete blood cell count (red cells, white blood cell, platelets), automated test
3. Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour
4. Infusion into a vein for therapy, prevention, or diagnosis
5. Injection beneath the skin or into muscle for therapy, diagnosis, or prevention
6. Injection of drug or substance into a vein for therapy, diagnosis, or prevention
7. Injection of different drug or substance into a vein for therapy, diagnosis, or prevention
8. Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle
9. Infusion of chemotherapy into a vein up to 1 hour
10. Infusion of chemotherapy into a vein
11. Irrigation of implanted venous access drug delivery device
12. New patient office or other outpatient visit, typically 60 minutes
13. New patient office or other outpatient visit, typically 60 minutes
14. Established patient office or other outpatient, visit typically 25 minutes
15. Established patient office or other outpatient, visit typically 25 minutes
16. Established patient office or other outpatient, visit typically 40 minutes
17. Established patient office or other outpatient, visit typically 40 minutes
18. Prolonged patient service without direct patient contact first hour
19. Injection, denosumab, 1 mg
20. Injection, ferric carboxymaltose, 1 mg